Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
04
04
2018
accepted:
25
09
2018
revised:
24
09
2018
pubmed:
18
11
2018
medline:
29
7
2020
entrez:
18
11
2018
Statut:
ppublish
Résumé
Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) with poor long-term survival after cytotoxic chemotherapy. Many novel drugs have revolutionized the treatment algorithms for MM. The impact of targeted therapy, both pre- and post-autologous stem cell transplant (auto-HCT) remains an area of ongoing interest. In this study, we report outcomes post auto-HCT for pPCL and the impact of maintenance therapy posttransplant with novel agents.
Identifiants
pubmed: 30446740
doi: 10.1038/s41409-018-0392-1
pii: 10.1038/s41409-018-0392-1
pmc: PMC8393277
mid: NIHMS1722682
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1089-1093Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Références
J Clin Oncol. 2016 Jun 20;34(18):2125-32
pubmed: 27114594
Leukemia. 2008 May;22(5):1044-52
pubmed: 18216867
Cancer. 2009 Dec 15;115(24):5734-9
pubmed: 19877113
Ann Hematol. 2002 Jul;81(7):362-7
pubmed: 12185504
Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-11
pubmed: 21813352
J Clin Oncol. 2014 Feb 20;32(6):587-600
pubmed: 24419113
N Engl J Med. 2012 May 10;366(19):1770-81
pubmed: 22571201
Leuk Lymphoma. 2007 Jul;48(7):1423-5
pubmed: 17613775
Crit Rev Oncol Hematol. 2012 May;82(2):141-9
pubmed: 21719304
Leukemia. 2014 Mar;28(3):690-3
pubmed: 24220275
Ann Oncol. 2012 Jun;23(6):1499-502
pubmed: 22039089
Leukemia. 2012 May;26(5):1091-7
pubmed: 22042147
J Oncol. 2009;2009:867380
pubmed: 20011654